Clostridium difficile-associated disease

Last reviewed: 24 Oct 2020

Last updated: 06 May 2020

06 May 2020

FDA warns of the potential risk of pathogenic bacteria transmission associated with fecal microbiota transplantation

The Food and Drug Administration (FDA) is warning healthcare providers to consider the potential risk of pathogenic bacteria transmission associated with fecal microbiota transplant (FMT) products, which may result in serious adverse reactions.

The agency has been made aware of six reports of infections caused by enteropathogenic Escherichia coli (EPEC) and Shiga toxin-producing Escherichia coli (STEC) that have occurred following investigational use of FMT. It suspects these infections were due to transmission of pathogenic organisms from FMT products supplied by a stool bank company based in the US. Two of these patients died; however, it is unknown whether STEC infection contributed to these deaths.

The FDA previously issued a safety alert in June 2019 warning that FMT may transmit multidrug-resistant organisms, leading to serious or life-threatening infections, particularly in patients who are immunocompromised. This followed two cases of immunocompromised adults who received FMT and developed invasive infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. One of the patients died.[74]

FMT is currently recommended as an option by the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America guidelines for patients with at least two recurrences and where antibiotic therapy has failed.[2]

See Management: approach

See Management: treatment algorithm

Original source of updateexternal link opens in a new window

Patients usually present with diarrhea, abdominal pain, and leukocytosis, and a history of recent antibiotic use. Other common symptoms include fever, abdominal tenderness, and distension.

Testing should be limited to patients with unexplained, new-onset diarrhea (defined as 3 or more unformed stools in 24 hours). Molecular testing alone or as part of a multistep algorithm is recommended depending on local institutional protocols. May be evidence of pseudomembranes on sigmoidoscopy or colonoscopy in some patients.

Treatment is to discontinue the inciting antimicrobial agent and start therapy with oral vancomycin or fidaxomicin. Surgery may be required in fulminant disease.

About 5% to 50% of treated patients have recurrence after discontinuation of therapy but most respond to a second course of therapy. Fecal microbiota transplantation may be recommended in patients with multiple recurrences.

Definition

Infection of the colon caused by the bacteria Clostridium difficile. Characterized by inflammation of the colon and the formation of pseudomembranes. Occurs in patients whose normal bowel flora has been disrupted by recent antibiotic use. Also known as pseudomembranous colitis, CDI, or CDAD. This topic covers the diagnosis and management of adults only.

The US Clinical and Laboratory Standards Institute announced a nomenclature change of the species name from Clostridium difficile to Clostridioides difficile in 2018; however, this name change has not been widely adopted yet.[1]

This topic focuses on the diagnosis and management of C difficile infection in adults only.